# Novo Nordisk Plunges 15% After Next-Gen Obesity Drug CagriSema Loses Head-to-Head Trial Against Eli Lilly's Zepbound

*2026-02-24 00:01 UTC · Business · 1 min read*

> Novo Nordisk stock crashed 15% after CagriSema achieved only 20.2% weight loss vs 23.6% for Eli Lilly's Zepbound in the REDEFINE 4 trial.

Novo Nordisk shares crashed over 15% on Monday after its next-generation weight loss drug CagriSema failed to match Eli Lilly's tirzepatide (sold as Zepbound) in the pivotal REDEFINE 4 trial. Over 84 weeks, CagriSema delivered 20.2% weight loss compared to 23.6% for tirzepatide — a 3.4-percentage-point gap that was statistically significant, meaning the drug failed its primary endpoint of non-inferiority.

The result is a major blow to Novo Nordisk, which had pinned its competitive strategy on CagriSema — a combination of semaglutide and cagrilintide — to reclaim ground in the booming obesity drug market. Eli Lilly shares rose 4% on the news, further cementing its dominance. Novo filed CagriSema for FDA approval late last year, with a decision expected by late 2026, but the failed trial raises questions about its commercial positioning.

## Sources

- [statnews.com](https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/)
- [cnbc.com](https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html)

---
TechTools News · https://techtools.cz/tools/news/article/373-novo-nordisk-plunges-15-after-next-gen-obesity-drug-cagrisema-loses-head-to
Česká verze: https://techtools.cz/tools/news/clanek/363-akcie-novo-nordisk-spadly-o-15-pote-co-lek-na-obezitu-cagrisema-prohral-prime
